PSYENCE BIOMEDICAL LTD (PBM:NASDAQ)
$3.34 -0.15 (-4.298%)
Analysed PSYENCE BIOMEDICAL LTD (PBM:NASDAQ) News Sources
Top Midday Gainers
17-04-2026
yahoo.com
Sector Update: Health Care Stocks Higher Friday Afternoon
17-04-2026
yahoo.com
Sector Update: Health Care Stocks Advance Late Afternoon
17-04-2026
yahoo.com
Trump Trade: President to sign order on psychedelic used for PTSD
17-04-2026
yahoo.com
Psychedelic Shares Rise Following Trump's Executive Order to Accelerate Treatments for Serious Mental Illness
20-04-2026
yahoo.com
Psyence BioMed Positioned as World's only Licensed Pharmaceutical Grade Ibogaine Supplier at Source
20-04-2026
yahoo.com
Psyence BioMed Initiates Patient Dosing in Phase IIb Trial Evaluating NPX-5 for Adjustment Disorder
23-04-2026
yahoo.com
FDA Fast-Tracks Psychedelic Drug Research Following Trump Directive; Psychedelic Drug Makers Gain
24-04-2026
yahoo.com
Weekly Roundup on the Cannabis Sector & Psychedelic Sector
27-04-2026
yahoo.com
Psyence BioMed Announces U.S. Strategic Engagement Initiative Focused on GMP Ibogaine Research and Manufacturing
15-05-2026
yahoo.com
What is the current price of PSYENCE BIOMEDICAL LTD (PBM:NASDAQ)?
The current price of PSYENCE BIOMEDICAL LTD (PBM:NASDAQ) is $3.34.
PSYENCE BIOMEDICAL LTD (PBM:NASDAQ) absolute price change since previous trading day?
The absolute price change of PSYENCE BIOMEDICAL LTD (PBM:NASDAQ) since the previous trading day is $-0.15.
PSYENCE BIOMEDICAL LTD (PBM:NASDAQ) percentage price change since previous trading day?
The percentage price change of PSYENCE BIOMEDICAL LTD (PBM:NASDAQ) since the previous trading day is -4.298%.
What is the most recent average sentiment score for PSYENCE BIOMEDICAL LTD (PBM:NASDAQ)?
The most recent average sentiment score for PSYENCE BIOMEDICAL LTD (PBM:NASDAQ) is 74 out of 100.
What is the most recent average sentiment for PSYENCE BIOMEDICAL LTD (PBM:NASDAQ)?
The most recent sentiment for PSYENCE BIOMEDICAL LTD (PBM:NASDAQ) is .
SEC-8K** Filing Available For PSYENCE BIOMEDICAL LTD (PBM:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.